why is tirzepatide dose higher than semaglutide and Injectable Correlated with Greatest Weight Loss Among GLP-1 Medications Switching Semaglutide to Tirzepatide |

Semaglutidea GLP-1 receptor agonistreduces appetite and slows digestion, with clinical trials showing an average 15% body weight loss over 68 weeks

Archives of General Psychiatry, 53(10), 924-932

Disclosures Sanjay Kalra has received speaker fees from Eli Lilly, Novo Nordisk and Sanofi and is a member of the journals Editorial Board

Typical mild reactions peak within 24 to 72 hours and usually improve with simple care, whereas spreading redness larger than a few inches, fever, or breathing difficulty requires urgent evaluation

Manufacturer savings programs from Novo Nordisk can reduce out-of-pocket costs for eligible patients

In light of this and other studies, GLP-1 manufacturers have asked for vision loss lawsuits to be consolidated into a group federal litigation